<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  
  
  
  <meta name="generator" content="Wowchemy 5.0.0-beta.0 for Hugo">
  

  

  
  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Samvel B. Gasparyan">

  
  
  
    
  
  <meta name="description" content="Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and &gt;40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76–0.97; P=0.01), death from any cause (HR 0.90, 95% CI 0.82–0.99; P=0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65–0.78; P&lt;0.001) and MACEs (HR 0.90, 95% CI 0.81–1.00; P=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524).
- [**Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER**](https://www.nature.com/articles/s41591-022-01971-4) was published in *Nature Medicine (2022): 28 (9), 1956–1964.*">

  
  <link rel="alternate" hreflang="en-us" href="https://gasparyan.co/publication/dapa-hf-deliver-pooled/">

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  

  
  
  
  <meta name="theme-color" content="#3f51b5">
  

  
  
  
  <script src="/js/mathjax-config.js"></script>
  

  
  
  
  
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.9.0/css/academicons.min.css" integrity="sha512-W4yqoT1+8NLkinBLBZko+dFB2ZbHsYLDdr50VElllRcNt2Q4/GSs6u71UHKxB7S6JEMCp5Ve4xjh3eGQl/HRvg==" crossorigin="anonymous">
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.css" integrity="sha512-1xoFisiGdy9nvho8EgXuXvnpR5GAMSjFwp40gSRE3NwdUdIMIKuPa7bqoUhLD0O/5tPNhteAsE5XyyMi5reQVA==" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.2.2/lazysizes.min.js" integrity="sha512-TmDwFLhg3UA4ZG0Eb4MIyT1O1Mb+Oww5kFG0uHqXsdbyZz9DcvYQhKpGgNkamAI6h2lGGZq2X8ftOJvF/XjTUg==" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-134157980-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-134157980-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  

  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu37ae94fde7f6135a8e8cfd653ea9ade8_11929814_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu37ae94fde7f6135a8e8cfd653ea9ade8_11929814_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://gasparyan.co/publication/dapa-hf-deliver-pooled/">

  
  
  
  
  
  
  
    
  
  
  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="og:site_name" content="Biostatistician">
  <meta property="og:url" content="https://gasparyan.co/publication/dapa-hf-deliver-pooled/">
  <meta property="og:title" content="Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER | Biostatistician">
  <meta property="og:description" content="Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and &gt;40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76–0.97; P=0.01), death from any cause (HR 0.90, 95% CI 0.82–0.99; P=0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65–0.78; P&lt;0.001) and MACEs (HR 0.90, 95% CI 0.81–1.00; P=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524).
- [**Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER**](https://www.nature.com/articles/s41591-022-01971-4) was published in *Nature Medicine (2022): 28 (9), 1956–1964.*"><meta property="og:image" content="https://gasparyan.co/publication/dapa-hf-deliver-pooled/featured.png">
  <meta property="twitter:image" content="https://gasparyan.co/publication/dapa-hf-deliver-pooled/featured.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2022-08-27T00:00:00&#43;00:00">
    
    <meta property="article:modified_time" content="2022-08-27T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://gasparyan.co/publication/dapa-hf-deliver-pooled/"
  },
  "headline": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER",
  
  "image": [
    "https://gasparyan.co/publication/dapa-hf-deliver-pooled/featured.png"
  ],
  
  "datePublished": "2022-08-27T00:00:00Z",
  "dateModified": "2022-08-27T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Pardeep S. Jhund"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Biostatistician",
    "logo": {
      "@type": "ImageObject",
      "url": "https://gasparyan.co/images/icon_hu37ae94fde7f6135a8e8cfd653ea9ade8_11929814_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": "Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and \u003e40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76–0.97; P=0.01), death from any cause (HR 0.90, 95% CI 0.82–0.99; P=0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65–0.78; P\u003c0.001) and MACEs (HR 0.90, 95% CI 0.81–1.00; P=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524).\n- [**Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER**](https://www.nature.com/articles/s41591-022-01971-4) was published in *Nature Medicine (2022): 28 (9), 1956–1964.*"
}
</script>

  

  


  


  





  <title>Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER | Biostatistician</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper  ">

  
  
  
    <script>window.wcDarkLightEnabled = true;</script>
  
  
    <script>const isSiteThemeDark = false;</script>
  
  
  <script src="/js/load-theme.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  <div class="page-header">
    












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Biostatistician</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Biostatistician</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts"><span>Posts</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#projects"><span>Projects</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#featured"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/talk/"><span>Talks</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      
      <li class="nav-item dropdown theme-dropdown">
        <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true">
          <i class="fas fa-moon" aria-hidden="true"></i>
        </a>
        <div class="dropdown-menu">
          <a href="#" class="dropdown-item js-set-theme-light">
            <span>Light</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-dark">
            <span>Dark</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-auto">
            <span>Automatic</span>
          </a>
        </div>
      </li>
      

      

    </ul>

  </div>
</nav>


  </div>

  <div class="page-body">
    <div class="pub">

  




















  
  


<div class="article-container pt-3">
  <h1>Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER</h1>

  

  


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span ><a href="/author/pardeep-s.-jhund/">Pardeep S. Jhund</a></span>, <span ><a href="/author/toru-kondo/">Toru Kondo</a></span>, <span ><a href="/author/jawad-h.-butt/">Jawad H. Butt</a></span>, <span ><a href="/author/kieran-f.-docherty/">Kieran F. Docherty</a></span>, <span ><a href="/author/brian-l.-claggett/">Brian L. Claggett</a></span>, <span ><a href="/author/akshay-s.-desai/">Akshay S. Desai</a></span>, <span ><a href="/author/muthiah-vaduganathan/">Muthiah Vaduganathan</a></span>, <span ><a href="/author/samvel-b.-gasparyan/">Samvel B. Gasparyan</a></span>, <span ><a href="/author/olof-bengtsson/">Olof Bengtsson</a></span>, <span ><a href="/author/daniel-lindholm/">Daniel Lindholm</a></span>, <span ><a href="/author/magnus-petersson/">Magnus Petersson</a></span>, <span ><a href="/author/anna-maria-langkilde/">Anna Maria Langkilde</a></span>, <span ><a href="/author/rudolf-a.-de-boer/">Rudolf A. de Boer</a></span>, <span ><a href="/author/david-demets/">David DeMets</a></span>, <span ><a href="/author/adrian-f.-hernandez/">Adrian F. Hernandez</a></span>, <span ><a href="/author/silvio-e.-inzucchi/">Silvio E. Inzucchi</a></span>, <span ><a href="/author/mikhail-n.-kosiborod/">Mikhail N. Kosiborod</a></span>, <span ><a href="/author/lars-k%C3%B8ber/">Lars Køber</a></span>, <span ><a href="/author/carolyn-s.-p.-lam/">Carolyn S. P. Lam</a></span>, <span ><a href="/author/felipe-a.-martinez/">Felipe A. Martinez</a></span>, <span ><a href="/author/marc-s.-sabatine/">Marc S. Sabatine</a></span>, <span ><a href="/author/sanjiv-j.-shah/">Sanjiv J. Shah</a></span>, <span ><a href="/author/scott-d.-solomon/">Scott D. Solomon</a></span>, <span ><a href="/author/john-j.-v.-mcmurray/">John J. V. McMurray</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    August 2022
  </span>
  

  

  

  
  
  
  
  

  
  

</div>

  











  



<div class="btn-links mb-3">
  
  








  





<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/dapa-hf-deliver-pooled/cite.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1038/s41591-022-01971-4" target="_blank" rel="noopener">
  DOI
</a>



</div>


</div>


<div class="article-header article-container featured-image-wrapper mt-4 mb-4" style="max-width: 440px; max-height: 584px;">
  <div style="position: relative">
    <img src="/publication/dapa-hf-deliver-pooled/featured.png" alt="" class="featured-image">
    <span class="article-header-caption">Image credit: <a href="https://www.nature.com/nm/"><strong>Springer Nature Limited</strong></a></span>
  </div>
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract"><p>Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (≤40% and &gt;40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76–0.97; P=0.01), death from any cause (HR 0.90, 95% CI 0.82–0.99; P=0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65–0.78; P&lt;0.001) and MACEs (HR 0.90, 95% CI 0.81–1.00; P=0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524).</p>
<ul>
<li><a href="https://www.nature.com/articles/s41591-022-01971-4"><strong>Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER</strong></a> was published in <em>Nature Medicine (2022): 28 (9), 1956–1964.</em></li>
</ul>
</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    

    <div class="space-below"></div>

    <div class="article-style"></div>

    






<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/source-themes/">Source Themes</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://gasparyan.co/publication/dapa-hf-deliver-pooled/&amp;text=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://gasparyan.co/publication/dapa-hf-deliver-pooled/&amp;t=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER&amp;body=https://gasparyan.co/publication/dapa-hf-deliver-pooled/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://gasparyan.co/publication/dapa-hf-deliver-pooled/&amp;title=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER%20https://gasparyan.co/publication/dapa-hf-deliver-pooled/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://gasparyan.co/publication/dapa-hf-deliver-pooled/&amp;title=Dapagliflozin%20across%20the%20range%20of%20ejection%20fraction%20in%20patients%20with%20heart%20failure:%20a%20patient-level,%20pooled%20meta-analysis%20of%20DAPA-HF%20and%20DELIVER" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    



  
  
  
    
  
  
  
  <div class="media author-card content-widget-hr">
    
      
      <a href="https://gasparyan.co/"><img class="avatar mr-3 avatar-circle" src="/author/samvel-b.-gasparyan/avatar_hu805be2d0cd11b3293ad906453806c9b9_1001537_270x270_fill_q90_lanczos_center.jpg" alt="Samvel B. Gasparyan"></a>
    

    <div class="media-body">
      <h5 class="card-title"><a href="https://gasparyan.co/">Samvel B. Gasparyan</a></h5>
      <h6 class="card-subtitle">Biostatistician</h6>
      <p class="card-text">Biostatistician in cardiovascular trials.</p>
      <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="/#contact" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="/media/resume20220321.pdf" >
        <i class="ai ai-cv"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.fr/citations?user=E-wGuxwAAAAJ&amp;hl=en&amp;oi=ao" target="_blank" rel="noopener">
        <i class="fas fa-graduation-cap"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://github.com/samve" target="_blank" rel="noopener">
        <i class="fab fa-github"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://orcid.org/0000-0002-4797-2208" target="_blank" rel="noopener">
        <i class="ai ai-orcid"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="http://linkedin.com/in/sgasparyan" target="_blank" rel="noopener">
        <i class="fab fa-linkedin"></i>
      </a>
    </li>
  
</ul>

    </div>
  </div>


  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  














  
  
  <div class="article-widget content-widget-hr">
    <h3>Related</h3>
    <ul>
      
      <li><a href="/publication/dapa-hf-recurrent/">Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF</a></li>
      
      <li><a href="/publication/comments-on-win-ratio/">Comments on &#39;Sample size formula for a win ratio endpoint&#39; by RX Yu and J. Ganju</a></li>
      
      <li><a href="/publication/hce-design/">Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial</a></li>
      
      <li><a href="/publication/dare-19-kidney/">Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection</a></li>
      
      <li><a href="/publication/dare-19-primary/">Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19)</a></li>
      
    </ul>
  </div>
  





  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">
  

  <p class="powered-by">
    © 2022 Samvel B. Gasparyan
  </p>

  
  






  <p class="powered-by">
    
    
    
    Published with
    <a href="https://wowchemy.com" target="_blank" rel="noopener">Wowchemy</a>  —
    the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">
    open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>

      
      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      

      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/highlight.min.js" integrity="sha512-TDKKr+IvoqZnPzc3l35hdjpHD0m+b2EC2SrLEgKDRWpxf2rFCxemkgvJ5kfU48ip+Y+m2XVKyOCD85ybtlZDmw==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/r.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/latex.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.js" integrity="sha512-SeiQaaDh73yrb56sTW/RgVdi/mMqNeM2oBwubFHagc5BkixSpP1fvqF47mKzPGWYSSy4RwbBunrJBQ4Co8fRWA==" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/wowchemy.min.d9d80f811e95b4b4f6df1eaaf297b05f.js"></script>

    






</body>
</html>
